Intersect ENT Inc

-0.33 (-1.97%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)543.52M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$28.08 Million
Adjusted EPS-$0.42
See more estimates
10-Day MA$16.81
50-Day MA$18.86
200-Day MA$20.12
See more pivots

Intersect ENT Inc Stock, NASDAQ:XENT

1555 Adams Drive, Menlo Park, California 94025
United States of America
Phone: +1.650.641.2100
Number of Employees: 406


Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.